This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Topotarget A/s. Active years: 2011.
Company Filing History:
Years Active: 2011
Title: The Innovative Contributions of Paul Kristjansen
Introduction
Paul Kristjansen is a notable inventor based in Copenhagen, Denmark. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on improving therapeutic methods for tumor cells, showcasing his dedication to advancing medical science.
Latest Patents
Kristjansen holds a patent for a method of treating tumor cells, which involves administering an effective amount of a topoisomerase-II poison, such as etoposide, in combination with a bis-dioxypiperazine, like dexrazoxane. This method is further enhanced by the application of radiation, providing a comprehensive approach to cancer treatment. His patent is a testament to his commitment to finding effective solutions for patients in need.
Career Highlights
Throughout his career, Paul Kristjansen has been associated with Topotarget A/S, a company dedicated to developing innovative cancer therapies. His work has not only contributed to the company's mission but has also positioned him as a key figure in the field of oncology research. With a focus on practical applications of his inventions, Kristjansen continues to push the boundaries of what is possible in cancer treatment.
Collaborations
Kristjansen has collaborated with esteemed colleagues, including Kenneth Hofland and Maxwell Sehested. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, ultimately leading to advancements in cancer treatment methodologies.
Conclusion
Paul Kristjansen's contributions to cancer treatment through his innovative patent and collaborative efforts highlight his importance in the field of medical research. His work continues to inspire advancements that may significantly impact patient care in the future.